Allogene Therapeutics, Inc. - ALLO

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
May 15, 2026 SCHEDULE 13G/A Citadel Advisors LLC 2.4% 5,795,242 View
May 15, 2026 SCHEDULE 13G/A Citadel Advisors Holdings LP 2.4% 5,795,242 View
May 15, 2026 SCHEDULE 13G/A Citadel GP LLC 2.4% 5,795,242 View
May 15, 2026 SCHEDULE 13G/A Citadel Securities LLC 0.3% 614,069 View
May 15, 2026 SCHEDULE 13G/A Citadel Securities Group LP 0.4% 1,059,878 View
May 15, 2026 SCHEDULE 13G/A Citadel Securities GP LLC 0.4% 1,059,878 View
May 15, 2026 SCHEDULE 13G/A Kenneth Griffin 2.8% 6,855,120 View
May 15, 2026 SCHEDULE 13G/A Lynx1 Capital Management LP 0.0% 0 View
May 15, 2026 SCHEDULE 13G/A Weston Nichols 0.0% 0 View
May 13, 2026 SCHEDULE 13G/A David D. Chang, M.D., Ph.D. 4.9% 12,297,354 View
May 13, 2026 SCHEDULE 13G/A Chang 2006 Family Trust 0.5% 1,201,108 View
May 13, 2026 SCHEDULE 13G/A JEC 2019 Trust 0.3% 856,044 View
May 13, 2026 SCHEDULE 13G/A RTC 2019 Trust 0.3% 856,044 View
May 13, 2026 SCHEDULE 13G/A Arie Belldegrun, M.D. 5.4% 13,466,383 View
May 13, 2026 SCHEDULE 13G/A Bellco Legacy LLC 0.2% 539,867 View
May 13, 2026 SCHEDULE 13G/A Bellco Legacy IV LLC 1.9% 4,710,120 View
May 13, 2026 SCHEDULE 13G/A Vida Ventures LLC 0.7% 1,798,163 View
May 13, 2026 SCHEDULE 13G/A Vida Ventures III, L.P. 0.7% 1,720,172 View
May 13, 2026 SCHEDULE 13G/A Vida Ventures III-A, L.P. 0.0% 3,965 View
Apr 23, 2026 SCHEDULE 13G Frazier Life Sciences Public Fund, L.P. 4.7% 16,205,306 View
Apr 23, 2026 SCHEDULE 13G FHMLSP, L.P. 4.7% 16,205,306 View
Apr 23, 2026 SCHEDULE 13G FHMLSP, L.L.C. 4.7% 16,205,306 View
Apr 23, 2026 SCHEDULE 13G Frazier Life Sciences X, L.P. 0.1% 306,906 View
Apr 23, 2026 SCHEDULE 13G FHMLS X, L.P. 0.1% 306,906 View
Apr 23, 2026 SCHEDULE 13G FHMLS X, L.L.C. 0.1% 306,906 View
Apr 23, 2026 SCHEDULE 13G Frazier Life Sciences XI, L.P. 0.2% 722,956 View
Apr 23, 2026 SCHEDULE 13G FHMLS XI, L.P. 0.2% 722,956 View
Apr 23, 2026 SCHEDULE 13G FHMLS XI, L.L.C. 0.2% 722,956 View
Apr 23, 2026 SCHEDULE 13G Frazier Life Sciences XII, L.P. 0.5% 1,561,500 View
Apr 23, 2026 SCHEDULE 13G FHMLS XII, L.P. 0.5% 1,561,500 View
Apr 23, 2026 SCHEDULE 13G FHMLS XII, L.L.C. 0.5% 1,561,500 View
Apr 23, 2026 SCHEDULE 13G James N. Topper 0.1% 306,906 View
Apr 23, 2026 SCHEDULE 13G Patrick J. Heron 0.1% 306,906 View
Feb 17, 2026 SCHEDULE 13G/A Arie Belldegrun, M.D. 5.8% 13,248,170 View
Feb 17, 2026 SCHEDULE 13G/A Bellco Legacy LLC 0.2% 539,867 View
Feb 17, 2026 SCHEDULE 13G/A Bellco Legacy IV LLC 2.1% 4,710,120 View
Feb 17, 2026 SCHEDULE 13G/A Vida Ventures LLC 0.8% 1,798,163 View
Feb 17, 2026 SCHEDULE 13G/A Vida Ventures III, L.P. 0.8% 1,720,172 View
Feb 17, 2026 SCHEDULE 13G/A Vida Ventures III-A, L.P. 0.0% 3,965 View
Feb 13, 2026 SCHEDULE 13G David D. Chang, M.D., Ph.D. 5.2% 12,101,223 View
Feb 13, 2026 SCHEDULE 13G Chang 2006 Family Trust 0.5% 1,201,108 View
Feb 13, 2026 SCHEDULE 13G JEC 2019 Trust 0.4% 856,044 View
Feb 13, 2026 SCHEDULE 13G RTC 2019 Trust 0.4% 856,044 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.